451 related articles for article (PubMed ID: 21123754)
1. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort.
Kim S; Swaminathan S; Shen L; Risacher SL; Nho K; Foroud T; Shaw LM; Trojanowski JQ; Potkin SG; Huentelman MJ; Craig DW; DeChairo BM; Aisen PS; Petersen RC; Weiner MW; Saykin AJ;
Neurology; 2011 Jan; 76(1):69-79. PubMed ID: 21123754
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
Han MR; Schellenberg GD; Wang LS;
BMC Neurol; 2010 Oct; 10():90. PubMed ID: 20932310
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide network-based pathway analysis of CSF t-tau/Aβ1-42 ratio in the ADNI cohort.
Cong W; Meng X; Li J; Zhang Q; Chen F; Liu W; Wang Y; Cheng S; Yao X; Yan J; Kim S; Saykin AJ; Liang H; Shen L;
BMC Genomics; 2017 May; 18(1):421. PubMed ID: 28558704
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide association and interaction studies of CSF T-tau/Aβ
Li J; Zhang Q; Chen F; Meng X; Liu W; Chen D; Yan J; Kim S; Wang L; Feng W; Saykin AJ; Liang H; Shen L;
Neurobiol Aging; 2017 Sep; 57():247.e1-247.e8. PubMed ID: 28641921
[TBL] [Abstract][Full Text] [Related]
5. Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.
Elias-Sonnenschein LS; Helisalmi S; Natunen T; Hall A; Paajanen T; Herukka SK; Laitinen M; Remes AM; Koivisto AM; Mattila KM; Lehtimäki T; Verhey FR; Visser PJ; Soininen H; Hiltunen M
PLoS One; 2013; 8(4):e59676. PubMed ID: 23573206
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
Ramos de Matos M; Ferreira C; Herukka SK; Soininen H; Janeiro A; Santana I; Baldeiras I; Almeida MR; Lleó A; Dols-Icardo O; Alcolea D; Benussi L; Binetti G; Paterlini A; Ghidoni R; Nacmias B; Meulenbroek O; van Waalwijk van Doorn LJC; Kuiperi HBJ; Hausner L; Waldemar G; Simonsen AH; Tsolaki M; Gkatzima O; Resende de Oliveira C; Verbeek MM; Clarimon J; Hiltunen M; de Mendonça A; Martins M
J Alzheimers Dis; 2018; 66(2):639-652. PubMed ID: 30320580
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
Shaw LM; Vanderstichele H; Knapik-Czajka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter W; Lee VM; Trojanowski JQ;
Ann Neurol; 2009 Apr; 65(4):403-13. PubMed ID: 19296504
[TBL] [Abstract][Full Text] [Related]
8. An Integrated Bioinformatics Approach for Identifying Genetic Markers that Predict Cerebrospinal Fluid Biomarker p-tau181/Aβ1-42 Ratio in ApoE4-Negative Mild Cognitive Impairment Patients.
Sun Y; Bresell A; Rantalainen M; Höglund K; Lebouvier T; Salter H;
J Alzheimers Dis; 2015; 45(4):1061-76. PubMed ID: 25720397
[TBL] [Abstract][Full Text] [Related]
9. Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers.
Alexopoulos P; Guo LH; Kratzer M; Westerteicher C; Kurz A; Perneczky R
Dement Geriatr Cogn Disord; 2011; 32(3):164-70. PubMed ID: 21997402
[TBL] [Abstract][Full Text] [Related]
10. Variations in the FRA10AC1 Fragile Site and 15q21 Are Associated with Cerebrospinal Fluid Aβ1-42 Level.
Li QS; Parrado AR; Samtani MN; Narayan VA;
PLoS One; 2015; 10(8):e0134000. PubMed ID: 26252872
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
12. A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42.
Sleegers K; Bettens K; De Roeck A; Van Cauwenberghe C; Cuyvers E; Verheijen J; Struyfs H; Van Dongen J; Vermeulen S; Engelborghs S; Vandenbulcke M; Vandenberghe R; De Deyn PP; Van Broeckhoven C;
Alzheimers Dement; 2015 Dec; 11(12):1452-1460. PubMed ID: 26086184
[TBL] [Abstract][Full Text] [Related]
13. SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease.
Ramirez A; van der Flier WM; Herold C; Ramonet D; Heilmann S; Lewczuk P; Popp J; Lacour A; Drichel D; Louwersheimer E; Kummer MP; Cruchaga C; Hoffmann P; Teunissen C; Holstege H; Kornhuber J; Peters O; Naj AC; Chouraki V; Bellenguez C; Gerrish A; ; ; Heun R; Frölich L; Hüll M; Buscemi L; Herms S; Kölsch H; Scheltens P; Breteler MM; Rüther E; Wiltfang J; Goate A; Jessen F; Maier W; Heneka MT; Becker T; Nöthen MM
Hum Mol Genet; 2014 Dec; 23(24):6644-58. PubMed ID: 25027320
[TBL] [Abstract][Full Text] [Related]
14. Serial MRI and CSF biomarkers in normal aging, MCI, and AD.
Vemuri P; Wiste HJ; Weigand SD; Knopman DS; Trojanowski JQ; Shaw LM; Bernstein MA; Aisen PS; Weiner M; Petersen RC; Jack CR;
Neurology; 2010 Jul; 75(2):143-51. PubMed ID: 20625167
[TBL] [Abstract][Full Text] [Related]
15. Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease.
Nho K; Kim S; Horgusluoglu E; Risacher SL; Shen L; Kim D; Lee S; Foroud T; Shaw LM; Trojanowski JQ; Aisen PS; Petersen RC; Jack CR; Weiner MW; Green RC; Toga AW; Saykin AJ;
BMC Med Genomics; 2017 May; 10(Suppl 1):29. PubMed ID: 28589856
[TBL] [Abstract][Full Text] [Related]
16. Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau.
Hohman TJ; Dumitrescu L; Barnes LL; Thambisetty M; Beecham G; Kunkle B; Gifford KA; Bush WS; Chibnik LB; Mukherjee S; De Jager PL; Kukull W; Crane PK; Resnick SM; Keene CD; Montine TJ; Schellenberg GD; Haines JL; Zetterberg H; Blennow K; Larson EB; Johnson SC; Albert M; Bennett DA; Schneider JA; Jefferson AL;
JAMA Neurol; 2018 Aug; 75(8):989-998. PubMed ID: 29801024
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels.
Slaets S; Le Bastard N; Martin JJ; Sleegers K; Van Broeckhoven C; De Deyn PP; Engelborghs S
J Alzheimers Dis; 2013; 36(4):759-67. PubMed ID: 23666174
[TBL] [Abstract][Full Text] [Related]
18. Combined Genome-Wide CSF Aβ-42's Associations and Simple Network Properties Highlight New Risk Factors for Alzheimer's Disease.
Souza MB; Araújo GS; Costa IG; Oliveira JR;
J Mol Neurosci; 2016 Jan; 58(1):120-8. PubMed ID: 26576771
[TBL] [Abstract][Full Text] [Related]
19. CSF-tau, CSF-Abeta1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity.
Ganzer S; Arlt S; Schoder V; Buhmann C; Mandelkow EM; Finckh U; Beisiegel U; Naber D; Müller-Thomsen T
J Neural Transm (Vienna); 2003 Oct; 110(10):1149-60. PubMed ID: 14523627
[TBL] [Abstract][Full Text] [Related]
20. Social Networks and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
Ma YH; Wang YY; Tan L; Xu W; Shen XN; Wang HF; Hou XH; Cao XP; Bi YL; Dong Q; Yang JL; Yu JT
J Alzheimers Dis; 2021; 81(1):263-272. PubMed ID: 33749650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
